Ubiquitination, an important type of protein posttranslational modification (PTM), plays a
crucial role in controlling substrate degradation and subsequently mediates the “quantity” …

Purpose This review provides an update on the current clinical, epidemiological and
pathophysiological evidence alongside the diagnostic, prevention and treatment approach …

Elranatamab is a humanized B-cell maturation antigen (BCMA)-CD3 bispecific antibody. In
the ongoing phase 2 MagnetisMM-3 trial, patients with relapsed or refractory multiple …

Background Daratumumab, a human IgGκ monoclonal antibody that targets CD38, induces
direct and indirect antimyeloma activity and has shown substantial efficacy as monotherapy …

The ubiquitin proteasome pathway was discovered in the 1980s to be a central component
of the cellular protein-degradation machinery with essential functions in homeostasis, which …

Immunoglobulin A nephropathy (IgAN) is the most common primary glomerulonephritis
worldwide. It is a leading cause of chronic kidney disease and progresses to end-stage …

Background Anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell
therapy has been shown to have activity in patients with relapsed or refractory multiple …

Tissue deposition of protein fibrils causes a group of rare diseases called systemic
amyloidoses. This Seminar focuses on changes in their epidemiology, the current approach …

Background Bortezomib with dexamethasone is a standard treatment option for relapsed or
refractory multiple myeloma. Carfilzomib with dexamethasone has shown promising activity …

The diagnosis and treatment of multiple myeloma has changed dramatically in the past
decade. The disease definition has been updated to include highly specific biomarkers in …